Kythera Biopharmaceuticals Inc. announced on Wednesday the pricing for its $125 million secondary offering as it anticipates FDA approval of its lead drug candidate, a treatment that dissolves fat in double chins....

Join our Membership to get the full story.


Are you a current Member? Sign In